Lynparza Triumphs in High-Risk Early Breast Cancer in OlympiA
Cancers | Free Full-Text | PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
OlympiA - Breast International Group
Paolo Tarantino on Twitter: "Adjuvant olaparib relevantly improved DFS in #OlimpyA, setting a new SoC for BRCA-mutant patients with EBC 🗓 Mark the date of March 16, not to miss this OlympiA
Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer - The ASCO Post
2017 Chabner Colloquium PARP inhibitors in breast cancer: Clinical development and future directions
OlympiA trial | Lynparza | Astrazeneca
Adjuvant Olaparib in BRCA-Mutated Breast Cancer: The OlympiA Trial
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative, Early Breast Cancer
Breast Cancer - Articles - Oncology · Hematology | healthbook
PDF) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 an
Publications | Frontier Science Scotland
Asco 2021 – full Olympia results sweep away Parp doubts | Evaluate
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative, Early Breast Cancer
LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | NEJM
Asco 2021 – full Olympia results sweep away Parp doubts | Evaluate
Inclusion criteria of the OlympiA study according to tumor subtype and... | Download Scientific Diagram
OlympiA Data Spur Update to ASCO Guideline on Hereditary Breast Cancer Treatment
Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial | Breast Cancer
Immunotherapy for early triple negative breast cancer: research agenda for the next decade | npj Breast Cancer
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer - ScienceDirect
Adjuvant olaparib prolongs survival for certain patients with early breast cancer
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative, Early Breast Cancer
